Trials
4 active
14 in total · 9 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.”In the company’s words, NCT05937750 on ClinicalTrials.gov
- Tested for
- Long Term Efficacy and Safety, Kidney Transplantation in Highly Sensitized Patients
- Main trialPhase 3
- “A prospective, post-authorisation long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort.”In the company’s words, NCT05937750 on ClinicalTrials.gov
- Other names
- IdeS · HMED-IdeS · IgG endopeptidase · Idefirix
Other drugs for Kidney Transplantation in Highly Sensitized Patients
- Migalastat HClAmicus Therapeutics · Phase 3
- XyloCore StrenghtIperboreal Pharma Srl · Phase 3
- TegoprubartEledon Pharmaceuticals · Phase 3
- SymvessHumacyte, Inc. · Phase 3
- RoxadustatAstellas · Phase 3
- RetatrutideEli Lilly · Phase 3
Coming up2
- 28 Feb 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 Apr 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials14
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Apr 2030 | A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group | |
| Phase 2Recruiting | 28 Feb 2027 | Imlifidase Prior to Kidney Transplant in Highly Sensitised Children | |
| Phase 3Completed | 20 Jun 2025 | Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx | |
| Phase 3Terminated | 23 Jun 2025 | A Study With Imlifidase in Anti-GBM Disease | |
| Phase 3Completed | 21 Apr 2026 | Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts | |
| Phase 2Completed | 12 Dec 2017 | A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test | |
| Phase 2Completed | 28 May 2022 | An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients | |
| Phase 2Terminated | 5 Feb 2024 | A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation | |
| Phase 2Completed | 27 Feb 2024 | A Study of Imlifidase in Patients With Guillain-Barré Syndrome | |
| Phase 1Terminated | 10 Oct 2025 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74) | |
| Phase 2Authorised | not given | An open-label, phase 2 trial to evaluate the efficacy and safety of a single intravenous administration of GNT0003 (an adeno-associated viral vector expressing the UGT1A1 transgene) following imlifidase pre-treatment in participants aged 16 years and older with severe Crigler-Najjar syndrome requiring daily phototherapy and presenting pre-existing anti-AAV8 antibodies. | |
| Phase 2Ended | not given | IMLIFIDASE IN LIVING DONOR RENAL TRANSPLANTATION: HIGHLY SENSITIZED RECIPIENTS (LIVEDES STUDY) | |
| Phase 2Authorised | not given | Imlifidase in ANCA-associated Vasculitis | |
| Phase 2Ended | not given | lmlifidase treatment tor acute inflammation in AQP4-lgG associated neuromyelitis optica spectrum disorder (DEFEAT NMOSD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026